-

Shareholder Alert: Robbins LLP Reminds Investors ForeScout Technologies, Inc. (FSCT) Sued for Misleading Shareholders

SAN DIEGO & SAN JOSE, Calif.--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of ForeScout Technologies, Inc. (NASDAQ: FSCT) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between February 7, 2019 and October 9, 2019. ForeScout provides network security products to various regions around the world.

If you suffered a loss as a result of ForeScout's misconduct, click here.

ForeScout Technologies, Inc. (FSCT) Accused of Misleading Shareholders

According to the complaint, in February 2019, ForeScout issued a press release that provided fiscal full year 2019 ("FY19") revenue guidance of $363.1 million to $373.1 million, representing year-over-year growth of 24%. Then, in May 2019, ForeScout raised its FY19 revenue guidance to $365.3 million to $375.3 million. When asked about "deal slippage" the Company was facing, ForeScout assured analysts that "every one of those deals is still in pipeline… [ForeScout] [has] a high degree of confidence [the deals] close for the year…they've just slipped a little bit" and ended by stating "there's still plenty of pipeline to deliver upon the guidance [ForeScout has] given you for the full year." Contrary to these assurances, on October 10, 2019, ForeScout announced disappointing third quarter 2019 financial results that lowered the quarter's revenue guidance to $90.6 million to $91.6 million from $98.8 million to $101.8 million, revealing that the Company was experiencing a material impact from the significant volatility it was facing in closing its large deals. On this news, ForeScout's stock price fell $14.63 per share, or more than 37%, to close at $24.57 per share.

ForeScout Technologies, Inc. (FSCT) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

NASDAQ:FSCT

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the uniQure N.V. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Allegations that un...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POMDoctor, Ltd. (NASDAQ: POM) securities between October 9, 2025 and December 11, 2025. POMDoctor claims to be "a leading online medical services platform for chronic diseases in China." For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigating Alleg...

Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Inovio Pharmaceuticals, Inc. Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP informs stockholders that a class action was filed on behalf of all persons that purchased or otherwise acquired Inovio Pharmaceuticals, Inc. (NASDAQ: INO) securities between October 10, 2023 and December 26, 2025. Inovio is a biotechnology company focused on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with, inter alia, human papillomavirus (“HPV”). For more information, submit a...
Back to Newsroom